News

GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
FDA approves GSK’s Nucala to treat COPD
GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...
BioSpace1h
GSK Wins COPD Expansion for Nucala After FDA Delay
The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...
pharmaphorum6h
GSK claims first approval for Nucala in COPD
While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...
FDA Approves GSK's Nucala for Expanded Use in COPD
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
The Pharma Letter3h
Nucala approved by FDA for use in adults with COPD
UK pharma major GSK (LSE: GSK) yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala ...
GSK's asthma drug wins FDA approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
Managed Healthcare Executive2h
FDA Approves Nucala as Maintenance Therapy for COPD
Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.
Le Lézard4h
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately ...
Medical Dialogues8h
GSK Nucala wins USFDA OK for use in adults with COPD
London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...
Contract Pharma1h
FDA Greenlights GSK’s Nucala for Eosinophilic COPD
The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.
Fierce Pharma19h
GSK revs up launch plans after Nucala's FDA approval in COPD, targeting £500M opportunity
The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...